Document Detail


Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation.
MedLine Citation:
PMID:  18256431     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Laboratory tools to monitor infection burden are important to evaluate progress and determine endpoints in programs to eliminate lymphatic filariasis. We evaluated changes in Wuchereria bancrofti microfilaria, filarial antigen and Bm14 antibody in individuals who participated in a five-year mass drug administration trial in Papua New Guinea. Comparing values before treatment and one year after four annual treatments, the proportion of microfilaria positive individuals declined to the greatest degree, with less marked change in antibody and antigen rates. Considering children as sentinel groups who reflect recent transmission intensity, children surveyed before the trial were more frequently microfilaria and antibody positive than those examined one year after the trial stopped. In contrast, antigen positive rates were similar in the two groups. All infection indicators continued to decline five years after cessation of mass drug administration; Bm14 antibody persisted in the greatest proportion of individuals. These data suggest that Bm14 antibody may be a sensitive test to monitor continuing transmission during and after mass drug administration aimed at eliminating transmission of lymphatic filariasis.
Authors:
Daniel J Tisch; Moses J Bockarie; Zachary Dimber; Benson Kiniboro; Nandao Tarongka; Fred E Hazlett; Will Kastens; Michael P Alpers; James W Kazura
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of tropical medicine and hygiene     Volume:  78     ISSN:  0002-9637     ISO Abbreviation:  Am. J. Trop. Med. Hyg.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-07     Completed Date:  2008-03-31     Revised Date:  2013-06-13    
Medline Journal Info:
Nlm Unique ID:  0370507     Medline TA:  Am J Trop Med Hyg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  289-93     Citation Subset:  AIM; IM    
Affiliation:
Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio 44106-7286, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Helminth / blood*
Antigens, Helminth / blood*
Antiparasitic Agents / administration & dosage,  therapeutic use*
Child
Child, Preschool
Diethylcarbamazine / therapeutic use
Drug Therapy, Combination
Elephantiasis, Filarial / drug therapy,  epidemiology,  immunology,  prevention & control*
Follow-Up Studies
Humans
Infant
Ivermectin / administration & dosage,  therapeutic use
Papua New Guinea / epidemiology
Wuchereria bancrofti / immunology*,  isolation & purification
Grant Support
ID/Acronym/Agency:
AI065717/AI/NIAID NIH HHS; U19 AI065717/AI/NIAID NIH HHS; U19 AI065717-01/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Helminth; 0/Antigens, Helminth; 0/Antiparasitic Agents; 0/Wuchereria antigen; 70288-86-7/Ivermectin; 90-89-1/Diethylcarbamazine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Predictors of compliance in mass drug administration for the treatment and prevention of lymphatic f...
Next Document:  Molecular identification of Trypanosoma cruzi I tropism for central nervous system in Chagas reactiv...